Mesalamine 1200 mg Tablet
Description
MESROOT-1.2
Mesalamine Delayed Release 1200 mg Tablets
Division: CHEMSROOT
Composition
Each delayed-release tablet contains:
Mesalamine IP — 1200 mg
Excipients — q.s.
Colour: Approved colour used
Dosage form: Delayed-release oral tablet
Product Description
MESROOT-1.2 contains Mesalamine Delayed Release 1200 mg, a high-strength anti-inflammatory aminosalicylate formulation designed for the treatment and maintenance of remission in ulcerative colitis and other inflammatory bowel diseases (IBD). The delayed-release formulation ensures targeted drug delivery to the colon, where Mesalamine exerts its local anti-inflammatory action on the intestinal mucosa.
Mesalamine is widely prescribed by gastroenterologists for patients with mild to moderate ulcerative colitis, extensive ulcerative colitis, pancolitis, and long-term maintenance therapy to reduce disease relapse. It helps decrease intestinal inflammation, promote mucosal healing, reduce rectal bleeding and diarrhea, and maintain long-term remission in patients with inflammatory bowel disease.
MESROOT-1.2 is particularly beneficial for patients requiring high-dose Mesalamine therapy, extensive colonic involvement, targeted colonic drug delivery, maintenance of remission, and effective anti-inflammatory treatment with minimal systemic absorption.
Technical Knowledge of Mesalamine Delayed Release
Mesalamine (5-aminosalicylic acid) acts locally within the intestinal mucosa by inhibiting cyclooxygenase and lipoxygenase pathways, reducing the synthesis of inflammatory prostaglandins and leukotrienes. It also modulates cytokine production, inhibits nuclear factor-kappa B (NF-kB) activation, reduces oxidative stress, and suppresses inflammatory cell migration within the colon.
The delayed-release tablet is formulated with pH-dependent coating technology that protects the drug from release in the stomach and proximal small intestine, allowing targeted release in the terminal ileum and colon, where inflammation is most prominent in ulcerative colitis.
Mechanism of Action
Mesalamine inhibits cyclooxygenase and lipoxygenase pathways, reduces prostaglandin and leukotriene synthesis, suppresses inflammatory cytokines, decreases oxidative stress, promotes mucosal healing, and reduces intestinal inflammation through local colonic action.
Key Benefits
Targets inflammation directly in the colon
Promotes mucosal healing
Helps induce and maintain remission in ulcerative colitis
Reduces rectal bleeding and diarrhea
Provides targeted delayed-release colonic delivery
Minimizes systemic drug exposure
Supports long-term inflammatory bowel disease management
Suitable for high-dose therapy under medical supervision
Clinical Applications
MESROOT-1.2 is commonly prescribed for mild to moderate ulcerative colitis, extensive ulcerative colitis, pancolitis, maintenance of ulcerative colitis remission, inflammatory bowel disease, long-term colonic anti-inflammatory therapy, and patients requiring high-dose Mesalamine treatment.
Facts About Mesalamine
Mesalamine is considered first-line therapy for mild to moderate ulcerative colitis and maintenance of remission. Delayed-release formulations are specifically designed to deliver the drug to the colon, improving therapeutic efficacy while minimizing systemic adverse effects. The 1200 mg delayed-release strength provides higher therapeutic dosing convenience, improved patient adherence, effective mucosal healing, and sustained remission maintenance in patients with extensive ulcerative colitis.
Key Facts
High-strength delayed-release aminosalicylate therapy
Mesalamine 1200 mg for targeted colonic anti-inflammatory treatment
Promotes mucosal healing and remission maintenance
Effective in extensive ulcerative colitis and inflammatory bowel disease
Minimizes systemic drug exposure
Evidence-based gastroenterology therapy
Quality-assured pharmaceutical formulation
PCD Pharma Franchise Opportunity
MESROOT-1.2 is an excellent product for PCD Pharma Franchise, Gastroenterology Franchise, and Specialty Pharma Franchise across India. The increasing prevalence of ulcerative colitis, inflammatory bowel disease, gastrointestinal inflammatory disorders, and long-term maintenance therapy creates strong prescription demand and excellent market potential for this formulation.
Why Choose MESROOT-1.2 for PCD Pharma Franchise?
High prescription potential
Strong gastroenterologist acceptance
Attractive monopoly franchise opportunity
Competitive pricing
Promotional support available
Visual aids and specialty marketing inputs
Consistent product quality
Excellent repeat business potential
Third Party Manufacturing
Chemsroot Pharmaceutical offers Third Party Manufacturing of Mesalamine Delayed Release 1200 mg Tablets with complete manufacturing support for pharmaceutical companies, marketers, exporters, and specialty gastroenterology businesses.
Our Third Party Manufacturing Services Include
Private label manufacturing
Contract manufacturing
Custom brand manufacturing
Loan license manufacturing
DCGI-compliant production
GMP-certified manufacturing
Batch manufacturing documentation
Product registration support
Customized packaging and artwork
Monopoly franchise packaging
Bulk manufacturing capability
Manufacturing Features
Pharmaceutical-grade raw materials
IP/BP/USP quality standards
In-process quality control
Finished product testing
Stability-oriented delayed-release formulation
Advanced pH-dependent coating technology
Blister and Alu-Alu packaging options
MESROOT-1.2 from CHEMSROOT combines targeted colonic anti-inflammatory therapy, high-strength mucosal healing support, evidence-based ulcerative colitis management, and high-quality pharmaceutical manufacturing, making it an ideal product for gastroenterologists, physicians, PCD Pharma Franchise partners, and Third Party Manufacturing clients seeking a reliable Mesalamine delayed-release formulation.
